Pulmonary Drug Delivery Systems Market Size, Share, Growth, Report By 2030

The global pulmonary drug delivery system market size was exhibited at USD 55.26 billion in 2022 and is projected to hit around USD 92.4 billion by 2032, growing at a CAGR of 6.6% from 2023 to 2030.

In a pulmonary drug delivery system, medication is inhaled via the lungs and enters the bloodstream via the alveolar epithelium. It is an alternative method to subcutaneous and also intravenous injection. It is a non-invasive method. It plays an essential role in the efficiency of pulmonary delivery. For respiratory delivery, many devices are used, such as nebulizers, metered-dose inhalers, and dry powder inhalers. These devices are adapted for use with protein/peptide drugs. In pulmonary drug delivery, patients use an inhaler to inhale their medications. It is used in treating lung diseases, for instance, asthma and chronic obstructive pulmonary disease (COPD). Drug particle properties, breathing patterns, and respiratory tract geometry affect its rate and efficacy. It lowers systemic side effects and increases bioavailability. 

Pulmonary drug delivery is used for inhaled beta-agonists, corticosteroids, and anticholinergic agents to treat asthma and COPD. The pulmonary route of administration offers various benefits. The drug is delivered directly to the disease site to treat respiratory diseases. It is provided to perform topical relief. Targeted drug delivery is delivering the drugs to the targeted area. It is a targeted drug delivery system. The drug is infused into the body via the pulmonary route. It is a better drug delivery alternative for treating asthma and chronic obstructive pulmonary disease. It provides quick relief from asthmatic attacks and acute bronchitis.  

Growth Factors 

The increasing air pollution level drives the global pulmonary drug delivery systems market. The surging prevalence of pulmonary diseases, such as asthma and chronic obstructive pulmonary disease, significantly contributes to market growth. The rising investments from private & government organizations for treating pulmonary diseases positively influence market growth. The growing awareness regarding pulmonary health catalyzes market growth. The increasing incidence of chronic obstructive pulmonary diseases and the development of pulmonary drug delivery systems propel the market growth. The escalating awareness of the management & treatment of pulmonary diseases favors market growth. 

The increasing number of hospitals & diagnostic centers offers numerous opportunities to expand the global pulmonary drug delivery system market. The presence of key manufacturing companies and the rising government initiatives for treating pulmonary diseases strengthen the market growth. The increasing incidence of respiratory infections and technological advancements favors market growth. The development of novel targeted drug delivery systems fuels the market growth. The rise in the number of initiatives undertaken by government and non-government organizations boosts the overall market growth.  

Pulmonary Drug Delivery Systems Market Report Scope

Report Highlights: 

• Based on the product, Metered Dose Inhalers (MDI) dominated the market due to the development of novel MDIs, the presence of global key players, and the acceptance of these devices. Dry Powder Inhaler (DPI) is expected to grow at a lucrative rate due to its benefits, such as cost-effectiveness, short administration, and preparation time. It is a device used for treating a diverse range of respiratory disorders. A nebulizer is expected to grow rapidly due to the high demand for this device in hospitals. It is also used in home care and emergency medicine. The accessories are expected to witness a promising CAGR due to extensive R&D and the increasing use of its efficient drug delivery to a patient’s lungs.  
• Based on the application, asthma dominated the market due to the increasing number of people affected by asthma and the rising demand for MDIs and DPIs for asthma management. The COPD segment is expected to witness dynamic growth due to the increasing incidence and mortality of COPD. Favorable reimbursement policies and growing government and nongovernment organizations' support for COPD treatment drive the segment's growth. The other application is anticipated to show progress due to the surging prevalence of chronic diseases. 
• Based on the distribution channel, Hospital pharmacies dominated the market due to their benefits, such as extensive treatments, care, quick reimbursements, and insurance policies. Retail pharmacies are anticipated to witness steady growth due to easy accessibility and affordability. The retail pharmacies provide home care products. E-commerce is expected to witness a promising CAGR due to its improved healthcare infrastructure and convenience.  
• Based on the end-use, hospitals dominated the market due to the launch of technologically advanced medical devices and their usage in hospitals. The hospital offers various treatments for various respiratory diseases. Home care is projected to witness lucrative growth due to the preference for home healthcare, the shortage of healthcare facilities, and the rising cost of healthcare services. The introduction of technologically advanced devices, which are portable and small-sized, drives the segment's growth.  

Regional Snapshots:

Based on the region, North America dominated the market due to the rising incidence of diseases such as COPD and asthma. The increasing number of patients affected by these diseases and the growing demand for diagnostic devices catalyze the growth of this region. The presence of pharmaceutical and medical device players, inflating disposable income, advanced healthcare infrastructure, geriatric population, and lifestyle changes are expected to drive the growth of the respiratory drug delivery devices market.

Asia Pacific region is expected to witness a promising CAGR due to the surging number of patients suffering from asthmatic and allergic rhinitis and an increasing number of supportive nongovernment organizations. The growing awareness about treating respiratory disorders amongst patients and continuous rising R&D activities by key market players support the growth of the Asia Pacific region. 

Market Dynamics

Market Driver: Increasing prevalence of chronic obstructive pulmonary disease (COPD) 

The increasing prevalence of chronic obstructive pulmonary disease (COPD) significantly contributes to global market growth. In line with this, the advantages of the pulmonary drug delivery route positively influence market growth. The product launches and rapid technological advancements create a positive outlook for the market. The marketing strategies adopted by the major players catalyze market growth. The growing adoption of pulmonary drug delivery and the launch of smart and digital inhalers strengthens market growth.  

Market Opportunity: Rising Awareness Campaign 

The rising awareness campaign to boost the uptake of pulmonary drug delivery devices offers lucrative opportunities for market growth. Government organizations across various countries are taking initiatives to conduct awareness campaigns to spread the importance and benefits of pulmonary drug delivery devices. The development of smart inhalers for asthma and COPD patients favors market growth. Many people are affected by pulmonary diseases, thereby accelerating product demand. The market players are introducing patient-friendly and cost-effective devices. The surging number of hospital admissions due to COPD drives the market growth. The increasing patient awareness regarding the benefits of DPIs and MDIs drives the market during the forecast period. 

Market Restraint: Patients’ Unawareness  

The unawareness among the population about nasal drug delivery techniques hampers market growth. The patients need to be made aware of the dose administration technique. This restricts the pulmonary drug delivery system market growth. The lack of training, understandability and incorrect usage impede the overall market revenue during the forecast period. 

Market Challenge: Regulatory Issues 

The stringent government regulations on the approval of pulmonary drug delivery systems challenge market growth. The high pricing pressures hamper the pulmonary drug delivery systems market growth.  

Key Developments: 

• In April 2019, Glenmark Pharmaceuticals Ltd. introduced one metered-dose inhaler called Soprobec. It also introduced breathe actuated inhaler named Stalpex. 
• In November 2019, Lupin introduced a device that tracks the usage pattern of the metered dose inhalers by COPD patients and termed it Adhero. 

Market Key Players:

• Philips Respironics
• GlaxoSmithKline PLC
• BoehringerIngelheim GmbH
• TevaPharmaceutical Industries Ltd.
• 3M Healthcare
• PARI GmbH
• F. Hoffmann-La Roche AG
• Gilbert Technologies
• AstraZeneca PLC
• Omron Healthcare, Inc.

Market Segmentation:

By Product

• Dry Powder Inhalers
• Nebulizers
• Metered Dose Inhalers
• Accessories

By Indication

• COPD
• Asthma
• Cystic Fibrosis
• Allergic Rhinitis
• Others

By Distribution Channel

• Retail Pharmacy
• Hospital Pharmacy
• E-Commerce

Buy this Research Report@ https://www.precedenceresearch.com/checkout/1502

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com| +1 9197 992 333